Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Symbiotec Pharmalab IPO
Price Band
₹938.0–988.0
Issue Size
₹1757.0 Cr
Lot Size
15 shares
Min Investment
₹14,820
GMP
+₹185.0 (18.72%)
Issue Price
₹988.0
Subject to Sauda
₹2100
Paid only if allotted
Symbiotec Pharmalab IPO AI Summary
- Symbiotec Pharmalab IPO is listed on BSE, NSE in the Pharmaceuticals sector.
- Price band: ₹938.0–₹988.0 per share, lot size 15 shares (min. investment ₹14,820).
- Subscription window: 24 Aug–27 Aug 2026, listing on 01 Sep 2026.
- Current GMP is +₹185.0 (18.72%), an estimated listing price of ₹1173 — unofficial and can change daily.
Symbiotec Pharmalab Ltd. is a pharmaceutical company with a strong focus on quality and sustainability, aiming to leverage its extensive experience and capabilities in the API market. The IPO has garnered significant interest, reflecting investor confidence in its growth potential.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Symbiotec Pharmalab IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 27 Aug 2026 — not a current signal.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Overall Subscription
75.08x
| Category | Subscription | Status |
|---|---|---|
| QIB (Institutional) |
181.20x
|
181x 🔥 |
| NII (HNI) |
77.56x
|
78x ✓ |
| ↳ bNII (>₹10L) |
87.34x
|
87x ✓ |
| ↳ sNII (<₹10L) |
58.01x
|
58x ✓ |
| Retail (RII) |
13.69x
|
14x ✓ |
| Employee |
16.32x
|
16x ✓ |
| Total | 75.08x | 75.08x |
Auto-updated every 5 min · As of 27th Aug 2026 18:56
Symbiotec Pharmalab IPO Grey Market Premium (GMP) Today
GMP
+₹185.0
GMP %
+18.72%
Est. Listing
₹1173.0
Updated: 01 Sep 2026 10:00
GMP Trend (Last 13 Days)
About the Company
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients, and specialty products. The company caters to domestic and international markets across regulated and emerging regions. It emphasizes research-driven manufacturing, quality compliance, and sustainable processes. Symbiotec Pharmalab Ltd. supports pharmaceutical, nutraceutical, and wellness industries by delivering high-quality, innovative ingredients aligned with global standards. With over 30 years of industry experience, they have evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations. As of June 30, 2025, they had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres. Competitive Strengths: Global leadership in corticosteroid and steroidal-hormone APIs Long-standing relationships with domestic and global customer base Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record. Continuous investment in R&D, with leading technological capabilities among Indian peers. Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings
Company Financials (₹ Cr)
As of 2026-03-31
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Key Ratios
EPS
₹17.82
NAV
₹150.17
ROE
12.66%
ROCE
11.80%
RoNW
11.79%
P/B Value
6.58
P/E Ratio
55.44
Market Cap
₹6244.43 Cr
PAT Margin
12.80%
Peer Comparison
| Company | RoNW | P/E (x) | EPS Basic | EPS Diluted | NAV |
|---|---|---|---|---|---|
| Laurus Labs | 16.8% | 109.36 | 16.47 | 16.45 | — |
| Cohance Lifesciences | 7% | 95.02 | 4.69 | 4.68 | — |
| Divi's Laboratories | 16.5% | 87.8 | 96.75 | 96.75 | 631 |
| Concord Biotech | 14% | 61.07 | 24.78 | 24.78 | — |
| Symbiotec Pharmalab This IPO | 9.48% | — | 19.1 | 19 | 184.69 |
Promoters
Anil Satwani, Kashish Satwani, Sushil Satwani, Satwani Holdings LLP
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company 112.50 2 General Corporate Purposes 29.53 3 Issue Expenses 105.02 Total 247.05
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹723.33 Cr in the year ending 31 Mar 2024, increasing to ₹755.98 Cr by 31 Mar 2025, and further rising to ₹872.26 Cr by 31 Mar 2026. This shows a consistent upward trend in revenue over the three periods.
Profit Trend
Profit After Tax was ₹100.06 Cr in the year ending 31 Mar 2024, which decreased to ₹96.79 Cr by 31 Mar 2025, before increasing to ₹109.90 Cr by 31 Mar 2026. This indicates a recovery in profits after a dip in the previous year.
Valuation
Symbiotec Pharmalab's implied P/E at the issue price is approximately 55.44, compared to peers trading at P/E ratios ranging from 61.07 to 109.36.
Grey Market Premium, Explained
The Grey Market Premium (GMP) is an unofficial indicator of the expected listing price of an IPO. It reflects the difference between the issue price and the expected market price on the listing day. A positive GMP suggests that the market anticipates a higher price than the issue price.
Subscription Demand
As of 27th August 2026, the IPO was subscribed 75.08 times overall, with significant interest from various categories: QIBs at 181.2 times, NIIs at 77.56 times, and Retail Investors at 13.69 times.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and risk tolerance. It's important to consider the company's growth potential and market conditions.
Who May Want to Wait
Investors who are risk-averse or those who prefer stable, established companies may want to avoid IPOs like this, which can be subject to market fluctuations and uncertainties.
IPO Timeline, Explained
The IPO opens for subscription on 24th August 2026 and closes on 27th August 2026. Allotment of shares will be finalized on 28th August 2026, with the listing expected on 1st September 2026.
Listing Gains — The Risk
While many investors hope to gain on listing day, it is important to remember that listing gains are not guaranteed. Market conditions can change rapidly, and the performance of the stock on its debut can be influenced by various factors.
This evaluation is generated from Symbiotec Pharmalab's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Symbiotec Pharmalab IPO GMP today?
Symbiotec Pharmalab IPO GMP today is +₹185.0 (18.72%), indicating an estimated listing price of ₹1173. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Symbiotec Pharmalab IPO?
The price band of Symbiotec Pharmalab IPO is ₹938.0–₹988.0 per share.
When does Symbiotec Pharmalab IPO open and close?
Symbiotec Pharmalab IPO opens on 24 August 2026 and closes on 27 August 2026.
When does Symbiotec Pharmalab IPO list on the stock exchange?
Symbiotec Pharmalab IPO listed on 01 September 2026 at ₹1173.0.
What is the lot size for Symbiotec Pharmalab IPO?
The lot size for Symbiotec Pharmalab IPO is 15 shares, requiring a minimum investment of ₹14,820.
What is the price band for the IPO?
The price band for the IPO is ₹938.0 to ₹988.0.
What is the minimum investment required?
The minimum investment required is ₹14,820.0.
What is the lot size for the IPO?
The lot size for the IPO is 15 shares.
When is the listing date?
The listing date is scheduled for 1st September 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium or discount of the IPO shares on the listing day.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
24 Aug 2026
Close
27 Aug 2026
Allotment
28 Aug 2026
Listing
01 Sep 2026
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Full Analysis
Should you apply? Company analysis, GMP explained & FAQs
Community Sentiment
What are other investors planning for Symbiotec Pharmalab?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.